Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:FLKS
- CUSIP: N/A
- Web: www.flex-pharma.com
Capitalization:- Market Cap: $72.03 million
- Outstanding Shares: 17,029,000
Average Prices:- 50 Day Moving Avg: $3.48
- 200 Day Moving Avg: $4.31
- 52 Week Range: $3.01 - $12.76
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.62
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $1.25 million
- Price / Sales: 57.63
- Book Value: $3.07 per share
- Price / Book: 1.38
Profitability:- EBIDTA: ($38,200,000.00)
- Net Margins: -3,043.70%
- Return on Equity: -60.50%
- Return on Assets: -57.21%
Debt:- Current Ratio: 17.08%
- Quick Ratio: 16.95%
Misc:- Average Volume: 54,527 shs.
- Beta: 3.33
- Short Ratio: 11.35
Frequently Asked Questions for Flex Pharma (NASDAQ:FLKS)
What is Flex Pharma's stock symbol?
Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."
How were Flex Pharma's earnings last quarter?
Flex Pharma, Inc. (NASDAQ:FLKS) released its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.13. The firm earned $0.24 million during the quarter, compared to analysts' expectations of $0.38 million. Flex Pharma had a negative net margin of 3,043.70% and a negative return on equity of 60.50%. View Flex Pharma's Earnings History.
When will Flex Pharma make its next earnings announcement?
Where is Flex Pharma's stock going? Where will Flex Pharma's stock price be in 2017?
5 brokers have issued 12-month target prices for Flex Pharma's shares. Their predictions range from $8.00 to $40.00. On average, they expect Flex Pharma's share price to reach $17.50 in the next year. View Analyst Ratings for Flex Pharma.
Are investors shorting Flex Pharma?
Flex Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totalling 565,205 shares, a decrease of 10.4% from the April 28th total of 630,914 shares. Based on an average daily volume of 49,496 shares, the days-to-cover ratio is currently 11.4 days.
Who are some of Flex Pharma's key competitors?
Some companies that are related to Flex Pharma include Recro Pharma (REPH), AVEO Pharmaceuticals (AVEO), Gemphire Therapeutics (GEMP), Fate Therapeutics (FATE), Vascular Biogenics (VBLT), Vital Therapies (VTL), Axsome Therapeutics (AXSM), Spring Bank Pharmaceuticals (SBPH), ProQR Therapeutics N.V. (PRQR), Proteostasis Therapeutics (PTI), Adverum Biotechnologies (ADVM), Arrowhead Pharmaceuticals (ARWR), Cellular Biomedicine Group (CBMG), Cidara Therapeutics (CDTX), Summit Therapeutics PLC (SUMM), Agile Therapeutics (AGRX), Pfenex (PFNX) and MaxCyte (MXCT).
Who are Flex Pharma's key executives?
Flex Pharma's management team includes the folowing people:
- Christoph H. Westphal M.D. Ph.D., Chairman of the Board
- John McCabe, Chief Financial Officer, Treasurer
- William K. McVicar Ph.D., Interim President, Interim Chief Executive Officer
- Kathie Lindemann, Chief Operating Officer
- Jennifer Cermak Ph.D., Vice President - Research & Development
- Robert Hadfield Ph.D., General Counsel, Secretary
- Elizabeth Woo M.D. Ph.D., Senior Vice President, Investor Relations and Corporate Communications
- Thomas C. Wessel M.D. Ph.D., Chief Medical Officer
- Jeffrey D. Capello, Director
- Roderick Mackinnon M.D, Director
When did Flex Pharma IPO?
(FLKS) raised $60 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.
Who owns Flex Pharma stock?
Flex Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (8.65%), Ameriprise Financial Inc. (2.30%), Massachusetts Financial Services Co. MA (2.12%), Vanguard Group Inc. (1.86%), C WorldWide Group Holding A S (1.66%) and FMR LLC (1.48%). Company insiders that own Flex Pharma stock include Christoph H Westphal, John P Mccabe, Marc D Kozin, Michelle Stacy, Roderick Mackinnon and Thomas Wessel. View Institutional Ownership Trends for Flex Pharma.
Who sold Flex Pharma stock? Who is selling Flex Pharma stock?
Flex Pharma's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Granite Point Capital Management L.P., JPMorgan Chase & Co., TIAA CREF Investment Management LLC and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for Flex Pharma.
Who bought Flex Pharma stock? Who is buying Flex Pharma stock?
Flex Pharma's stock was purchased by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Royce & Associates LP, Spark Investment Management LLC, C WorldWide Group Holding A S, Vanguard Group Inc., Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Flex Pharma stock in the last two years include Christoph H Westphal, John P Mccabe, Marc D Kozin, Michelle Stacy, Roderick Mackinnon and Thomas Wessel. View Insider Buying and Selling for Flex Pharma.
How do I buy Flex Pharma stock?
Shares of Flex Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flex Pharma's stock price today?
One share of Flex Pharma stock can currently be purchased for approximately $4.23.
MarketBeat Community Rating for Flex Pharma (NASDAQ FLKS)MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Flex Pharma (NASDAQ:FLKS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | $17.50 (313.71% upside) |
Analysts' Ratings History for Flex Pharma (NASDAQ:FLKS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/4/2017 | Jefferies Group LLC | Lower Price Target | Buy | $9.00 -> $8.00 | High |  |
| 3/8/2017 | Piper Jaffray Companies | Set Price Target | Buy | $12.00 | Low | |
| 11/3/2016 | JMP Securities | Reiterated Rating | Buy | | N/A | |
| 11/2/2016 | Cantor Fitzgerald | Set Price Target | Hold | $10.00 | N/A | |
| 10/15/2016 | HC Wainwright | Reiterated Rating | Buy | $40.00 | N/A | |
| 4/12/2016 | Roth Capital | Lower Price Target | | $27.00 -> $24.00 | N/A | |
(Data available from 6/27/2015 forward)
Earnings History for Flex Pharma (NASDAQ:FLKS)Earnings History by Quarter for Flex Pharma (NASDAQ FLKS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/1/2017 | | | | | | | | |
| 5/3/2017 | Q1 2017 | ($0.62) | ($0.49) | $0.38 million | $0.24 million | View | Listen | |
| 3/8/2017 | Q4 2016 | ($0.84) | ($0.48) | $0.09 million | $0.30 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.72) | ($0.65) | $0.15 million | $0.60 million | View | Listen | |
| 8/3/2016 | Q216 | ($0.67) | ($0.71) | $0.01 million | $0.11 million | View | Listen | |
| 5/4/2016 | Q1 | ($0.56) | ($0.61) | | | View | Listen | |
| 3/8/2016 | Q415 | ($0.56) | ($0.51) | | | View | Listen | |
| 11/4/2015 | Q315 | ($0.44) | ($0.53) | | | View | Listen | |
| 8/5/2015 | Q215 | ($0.37) | ($0.47) | | | View | Listen | |
| 5/6/2015 | Q1 | ($0.32) | ($0.59) | | | View | Listen | |
| 3/17/2015 | Q4 | ($0.12) | ($1.82) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Flex Pharma (NASDAQ:FLKS)2017 EPS Consensus Estimate: ($2.03)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.39) | ($0.39) | ($0.39) |
| Q2 2017 | 1 | ($0.46) | ($0.46) | ($0.46) |
| Q3 2017 | 1 | ($0.56) | ($0.56) | ($0.56) |
| Q4 2017 | 1 | ($0.62) | ($0.62) | ($0.62) |
(Data provided by Zacks Investment Research)
Dividend History for Flex Pharma (NASDAQ:FLKS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Flex Pharma (NASDAQ:FLKS)Insider Ownership Percentage: 45.36%
Institutional Ownership Percentage: 29.50%
Insider Trades by Quarter for Flex Pharma (NASDAQ:FLKS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/8/2016 | Christoph H Westphal | Insider | Buy | 7,000 | $7.31 | $51,170.00 | |
| 11/7/2016 | Christoph H Westphal | Insider | Buy | 8,870 | $5.70 | $50,559.00 | |
| 11/7/2016 | John P Mccabe | VP | Buy | 1,650 | $6.01 | $9,916.50 | |
| 6/23/2016 | Christoph H Westphal | CEO | Buy | 2,700 | $11.28 | $30,456.00 | |
| 6/22/2016 | Christoph H Westphal | CEO | Buy | 5,700 | $11.05 | $62,985.00 | |
| 6/21/2016 | Christoph H Westphal | CEO | Buy | 2,800 | $11.07 | $30,996.00 | |
| 6/20/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $11.18 | $67,080.00 | |
| 6/16/2016 | Christoph H Westphal | CEO | Buy | 5,800 | $11.17 | $64,786.00 | |
| 6/14/2016 | Christoph H Westphal | CEO | Buy | 5,900 | $11.54 | $68,086.00 | |
| 6/10/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $11.94 | $71,640.00 | |
| 6/8/2016 | Christoph H Westphal | CEO | Buy | 5,900 | $12.25 | $72,275.00 | |
| 6/6/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $12.56 | $75,360.00 | |
| 6/2/2016 | Christoph H Westphal | CEO | Buy | 10,000 | $12.99 | $129,900.00 | |
| 5/31/2016 | Christoph H Westphal | CEO | Buy | 22,300 | $12.68 | $282,764.00 | |
| 5/26/2016 | Christoph H Westphal | CEO | Buy | 28,600 | $12.84 | $367,224.00 | |
| 5/24/2016 | Christoph H Westphal | CEO | Buy | 30,334 | $12.42 | $376,748.28 | |
| 5/20/2016 | Christoph H Westphal | CEO | Buy | 7,914 | $11.06 | $87,528.84 | |
| 5/18/2016 | Christoph H Westphal | CEO | Buy | 33,400 | $11.10 | $370,740.00 | |
| 5/16/2016 | Christoph H Westphal | CEO | Buy | 15,469 | $10.25 | $158,557.25 | |
| 5/12/2016 | Christoph H Westphal | CEO | Buy | 30,217 | $10.12 | $305,796.04 | |
| 5/10/2016 | Christoph H Westphal | CEO | Buy | 30,109 | $9.94 | $299,283.46 | |
| 3/24/2016 | Christoph H Westphal | CEO | Buy | 49,563 | $11.06 | $548,166.78 | |
| 3/22/2016 | Christoph H Westphal | CEO | Buy | 23,951 | $11.78 | $282,142.78 | |
| 3/21/2016 | Christoph H Westphal | CEO | Buy | 48,058 | $11.74 | $564,200.92 | |
| 3/18/2016 | Christoph H Westphal | CEO | Buy | 37,574 | $11.00 | $413,314.00 | |
| 3/16/2016 | Christoph H Westphal | CEO | Buy | 38,379 | $10.23 | $392,617.17 | |
| 3/15/2016 | Michelle Stacy | Director | Buy | 2,585 | $9.63 | $24,893.55 | |
| 3/14/2016 | Thomas Wessel | Insider | Buy | 20,000 | $7.94 | $158,800.00 | |
| 3/11/2016 | Christoph H Westphal | CEO | Buy | 89,680 | $7.00 | $627,760.00 | |
| 3/11/2016 | Roderick Mackinnon | Director | Buy | 10,000 | $7.03 | $70,300.00 | |
| 12/14/2015 | Christoph H Westphal | CEO | Buy | 927 | $12.01 | $11,133.27 | |
| 12/7/2015 | Christoph H Westphal | CEO | Buy | 907 | $12.02 | $10,902.14 | |
| 11/19/2015 | Marc D Kozin | Director | Buy | 4,500 | $11.38 | $51,210.00 | |
| 11/16/2015 | Christoph H Westphal | CEO | Buy | 1,001 | $10.78 | $10,790.78 | |
| 11/9/2015 | Christoph H Westphal | CEO | Buy | 1,000 | $11.03 | $11,030.00 | |
| 10/26/2015 | Christoph H Westphal | CEO | Buy | 1,043 | $10.55 | $11,003.65 | |
| 10/19/2015 | Christoph H Westphal | CEO | Buy | 1,018 | $10.61 | $10,800.98 | |
| 9/28/2015 | Christoph H Westphal | CEO | Buy | 924 | $11.18 | $10,330.32 | |
| 3/30/2015 | Christoph H Westphal | CEO | Buy | 272 | $20.52 | $5,581.44 | |
(Data available from 1/1/2013 forward)
Headline Trends for Flex Pharma (NASDAQ:FLKS)
Latest Headlines for Flex Pharma (NASDAQ:FLKS)
| Source: |
|
| Date | Headline |
|---|
 | Flex Pharma, Inc. (FLKS) Expected to Announce Quarterly Sales of $460,000.00
www.americanbankingnews.com - June 24 at 10:40 AM |
| Brokerages Expect Flex Pharma, Inc. (FLKS) to Post -$0.63 Earnings Per Share
www.americanbankingnews.com - June 22 at 8:18 AM |
| Flex Pharma Inc (FLKS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 6 at 8:42 AM |
 | Flex Pharma Announces Executive Leadership Transition
finance.yahoo.com - June 5 at 5:20 PM |
| Flex Pharma Inc (FLKS) Short Interest Down 10.4% in May
www.americanbankingnews.com - June 4 at 8:20 AM |
 | Flex Pharma (FLKS) Announces Endorsement of Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth by Inherited Neuropathies Consortium
www.streetinsider.com - June 2 at 6:33 PM |
| Flex Pharma’s Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium
finance.yahoo.com - June 2 at 8:19 AM |
| Flex Pharma Presenting at Upcoming Investor Conferences in June 2017
finance.yahoo.com - May 30 at 11:16 AM |
| Flex Pharma Inc (FLKS) Expected to Post Quarterly Sales of $460,000.00
www.americanbankingnews.com - May 28 at 7:48 AM |
| -$0.74 Earnings Per Share Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - May 27 at 12:30 AM |
| Flex Pharma Inc (FLKS) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 23 at 8:43 PM |
| Flex Pharma Inc (FLKS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 12 at 8:48 AM |
| Flex Pharma Inc Expected to Earn Q2 2017 Earnings of ($0.46) Per Share (FLKS)
www.americanbankingnews.com - May 8 at 8:21 AM |
| Flex Pharma Inc (FLKS) Expected to Announce Quarterly Sales of $530,000.00
www.americanbankingnews.com - May 5 at 3:14 PM |
| Flex Pharma Inc (FLKS) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - May 4 at 1:21 PM |
| Edited Transcript of FLKS earnings conference call or presentation 3-May-17 12:45pm GMT
finance.yahoo.com - May 4 at 12:23 PM |
| Flex Pharma (FLKS) Earning Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 4 at 1:21 AM |
| Flex Pharma Inc (FLKS) Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS
www.americanbankingnews.com - May 3 at 6:26 PM |
| Flex Pharma Inc (FLKS) Expected to Post Earnings of -$0.63 Per Share
www.americanbankingnews.com - May 3 at 2:06 PM |
| Flex Pharma Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 10:25 AM |
| Flex Pharma reports 1Q loss
finance.yahoo.com - May 3 at 10:25 AM |
| Flex Pharma (FLKS) Given Daily News Impact Rating of -0.08
www.americanbankingnews.com - April 30 at 11:57 AM |
| Flex Pharma (FLKS) Given Daily Media Sentiment Score of -0.16
www.americanbankingnews.com - April 27 at 5:06 PM |
| FDA Clears Flex Pharma's FLX-787 to Commence US Phase 2 Trial in ALS Under IND
finance.yahoo.com - April 26 at 8:11 PM |
| Flex Pharma (FLKS) Getting Somewhat Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 21 at 4:10 PM |
| Flex Pharma Announce Presentation of Human Efficacy Data on FLX-787 at American Academy of Neurology Annual Meeting on 4/27
www.streetinsider.com - April 19 at 5:07 PM |
| Flex Pharma Presents Human Efficacy Data on FLX-787 at the American Academy of Neurology Annual Meeting
finance.yahoo.com - April 19 at 12:04 PM |
| Flex Pharma (FLKS) Receives Daily News Sentiment Rating of -0.20
www.americanbankingnews.com - April 18 at 8:32 AM |
| Flex Pharma Inc (FLKS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 17 at 12:38 PM |
| Flex Pharma (FLKS) Receiving Somewhat Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 11:45 AM |
| Brokerages Expect Flex Pharma Inc (FLKS) Will Post Quarterly Sales of $380,000.00
www.americanbankingnews.com - April 14 at 1:58 PM |
| Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development
finance.yahoo.com - April 7 at 9:51 AM |
| Newly-Published Study Reinforces Efficacy Of HOTSHOT® In Preventing And Treating Muscle Cramps
finance.yahoo.com - March 23 at 5:42 PM |
| Brokers Set Expectations for Flex Pharma Inc's FY2017 Earnings (FLKS)
www.americanbankingnews.com - March 23 at 9:47 AM |
| Flex Pharma Inc (FLKS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 21 at 12:01 PM |
| FLEX PHARMA, INC. Financials
finance.yahoo.com - March 14 at 4:31 PM |
| Edited Transcript of FLKS earnings conference call or presentation 8-Mar-17 1:30pm GMT
finance.yahoo.com - March 9 at 5:43 PM |
| Flex Pharma Inc (FLKS) Issues Quarterly Earnings Results, Beats Estimates By $0.26 EPS
www.americanbankingnews.com - March 9 at 12:21 PM |
 | Flex Pharma's (FLKS) CEO Christoph Westphal on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 4:04 AM |
 | Flex Pharma Reports Year End 2016 Financial Results
us.rd.yahoo.com - March 8 at 6:01 PM |
| Q4 2016 Flex Pharma Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 8 at 6:01 PM |
| FLEX PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 8 at 6:01 PM |
| Flex Pharma to Report Fourth Quarter and Full Year 2016 Results on March 8, 2017
finance.yahoo.com - March 1 at 4:55 PM |
| Champion Triathlete Finds Solution For Struggle With Muscle Cramps
finance.yahoo.com - February 16 at 5:10 PM |
| Flex Pharma to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 6:29 PM |
| Flex Pharma (FLKS) to Prioritize Phase 2 Clinical Programs in Severe Neurological Diseases
www.streetinsider.com - January 24 at 10:55 PM |
| Flex Pharma (FLKS) to Prioritize Phase 2 Clinical Programs in ... - StreetInsider.com
www.streetinsider.com - January 24 at 5:54 PM |
| Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases
finance.yahoo.com - January 24 at 5:54 PM |
| 7:31 am Flex Pharma announces it is prioritizing its clinical programs in ALS, MS, and peripheral neuropathies such as Charcot-Marie Tooth
finance.yahoo.com - January 24 at 5:54 PM |
| Champion Pro Football Fullback Goes On The Offense Against Game-Changing Cramps
finance.yahoo.com - December 20 at 8:42 PM |
Flex Pharma (FLKS) Chart for Tuesday, June, 27, 2017
